Company intelligence / Profile preview

Newfoundland Diagnostics

Amersham, Buckinghamshire, United Kingdom

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Newfoundland Diagnostics has commercialized over 20 types of at-home diagnostic tests with reported clinical accuracy between 90–99.9%, used widely across the UK and globally, with major NHS deployments and over 100 million tests sold.

Therapeutic areas: NephrologyCardiovascularImmunologyEndocrinologyRheumatologyGastroenterologyInfectious DiseasesWomen's HealthHematologyMen's HealthPsychiatry
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

NHSTeam GBTescoAvicennaTerrence Higgins TrustThe Royal Marsden HospitalThe Trussell Trust

Beyond the preview

Go deeper on Newfoundland Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newfoundland Diagnostics.

Explore the full profile